Published in Drug Law Weekly, April 5th, 2011
Philadelphia, PA, London, UK, - Thomson Reuters announced the launch of the Newport Biologics Module, the most essential source of competitive intelligence for the rapidly growing market in biologic and biosimilar drugs.
The development of biological drugs has seen a dramatic increase during the past five years with nearly 6,000 clinical trials with a biological intervention being reported since 2005, according to Thomson Reuters. With this increase have come new government regulations promoting competition in the sector.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.